BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Why Large-Outcome RCTs?

Recent CV Outcome Trials with DPP-4 Inhibitors and GLP-1 Receptor Agonists

SAVOR-TIMI 53: Primary Endpoint

SAVOR-TIMI 53: Hospitalization for HF

SAVOR-TIMI 53: Patients at Risk for HF

EXAMINE: Primary Endpoint

EXAMINE: Hospitalization for HF

TECOS: Effect of Sitagliptin vs Placebo on CV Outcomes in T2DM

TECOS: Hospitalization for HF

TECOS: HF and Mortality Outcomes in Patients With Prior HF

TECOS: Non-CV Outcomes

ELIXA: CV Outcomes by Treatment Group

ELIXA: CV Death + HF Hospitalization by History of HF

ELIXA: Symptomatic Hypoglycemia: Time to First Event

ELIXA Safety Summary: AEs by Treatment

ELIXA Safety Summary: Other

New CV Outcome Trial with an SGLT2 Inhibitor: EMPA-REG OUTCOME

EMPA-REG OUTCOME: Trial Design

EMPA-REG OUTCOME: 3-Point MACE*

3-point MACE: Subgroup Analysis

EMPA-REG OUTCOME: CV Death

CV Death: Subgroup Analyses

EMPA-REG OUTCOME: CV Death, MI, and Stroke

EMPA-REG OUTCOME: All-cause Mortality

EMPA-REG OUTCOME: Hospitalizations for HF

EMPA-REG OUTCOME: AEs*

EMPA-REG OUTCOME Study: Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)